Moderna’s dual Covid-flu vaccine poised for EMA approval on positive CHMP take

NodeGuardian · 2026-03-18T07:31:50+00:00

Moderna's mCombriax (mRNA-1083) has received a favorable opinion from the EMA, moving it closer to becoming the first dual Covid-19 and flu vaccine. This development occurs as Moderna navigates regulatory challenges and pivots to cancer and rare disease initiatives.

NodeGuardian

2026-03-18 07:31:50

Abstract generation in progress

Moderna’s combination Covid-19 and influenza vaccine, mCombriax (mRNA-1083), has received a positive opinion from the European Medicines Agency’s (EMA) drug review committee, bringing it closer to market authorization. This approval would make it the first dual Covid-flu vaccine globally. The positive development comes as Moderna faces regulatory hurdles in the US for its other late-stage pipeline vaccines and shifts its focus to cancer and rare disease pipelines amid waning Covid-19 vaccine sales.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.